Regulatory aspects of optical methods and exogenous targets for cancer detection

Academic Article

Abstract

  • © 2017 American Association for Cancer Research. Considerable advances in cancer-specific optical imaging have improved the precision of tumor resection. In comparison to traditional imaging modalities, this technology is unique in its ability to provide real-time feedback to the operating surgeon. Given the significant clinical implications of optical imaging, there is an urgent need to standardize surgical navigation tools and contrast agents to facilitate swift regulatory approval. Because fluorescence-enhanced surgery requires a combination of both device and drug, each may be developed in conjunction, or separately, which are important considerations in the approval process. This report is the result of a oneday meeting held on May 4, 2016 with officials from the National Cancer Institute, the FDA, members of the American Society of Image-Guided Surgery, and members of the World Molecular Imaging Society, which discussed consensus methods for FDA-directed human testing and approval of investigational optical imaging devices as well as contrast agents for surgical applications. The goal of this workshop was to discuss FDA approval requirements and the expectations for approval of these novel drugs and devices, packaged separately or in combination, within the context of optical surgical navigation. In addition, the workshop acted to provide clarity to the research community on data collection and trial design. Reported here are the specific discussion items and recommendations from this critical and timely meeting.
  • Authors

    Digital Object Identifier (doi)

    Author List

  • Tummers WS; Warram JM; Tipirneni KE; Fengler J; Jacobs P; Shankar L; Henderson L; Ballard B; Pogue BW; Weichert JP
  • Start Page

  • 2197
  • End Page

  • 2206
  • Volume

  • 77
  • Issue

  • 9